First Time Loading...

E-Therapeutics PLC
LSE:ETX

Watchlist Manager
E-Therapeutics PLC Logo
E-Therapeutics PLC
LSE:ETX
Watchlist
Price: 9.4 GBX -3.59% Market Closed
Updated: May 4, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

475k
+61%
Revenue
Growth Rates:
1 Year
0%
3 Years
+4%
5 Years
-
7 Years
-
10 Years
-
-10.2m
+4%
Operating Income
Growth Rates:
1 Year
-7%
3 Years
-255%
5 Years
-51%
7 Years
+11%
10 Years
-95%
-8.3m
+9%
Net Income
Growth Rates:
1 Year
-3%
3 Years
-253%
5 Years
-54%
7 Years
+6%
10 Years
-98%

Earnings Waterfall
E-Therapeutics PLC

Revenue
475k GBP
Cost of Revenue
0 GBP
Gross Profit
475k GBP
Operating Expenses
-10.7m GBP
Operating Income
-10.2m GBP
Other Expenses
2m GBP
Net Income
-8.3m GBP

Income Statement
E-Therapeutics PLC

Rotate your device to view
Income Statement
Currency: GBP
Jan-2008 Jul-2008 Jan-2009 Jul-2009 Jan-2010 Jul-2010 Jan-2011 Jul-2011 Jan-2012 Jul-2012 Jan-2013 Jul-2013 Jan-2014 Jul-2014 Jan-2015 Jul-2015 Jan-2016 Jul-2016 Jan-2017 Jul-2017 Jan-2018 Jul-2018 Jan-2019 Jul-2019 Jan-2020 Jul-2020 Jan-2021 Jul-2021 Jan-2022 Jul-2022 Jan-2023
Revenue
Revenue
0
N/A
0
+67%
0
-30%
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
+427%
0
+97%
0
-33%
0
+4%
1
+139%
0
-37%
0
-38%
0
+61%
Gross Profit
Cost of Revenue
(0)
(0)
(0)
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
N/A
(0)
N/A
0
N/A
(0)
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
+427%
0
+97%
0
-33%
0
+4%
1
+139%
0
-37%
0
-38%
0
+61%
Operating Income
Operating Expenses
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(4)
(4)
(5)
(6)
(7)
(9)
(10)
(11)
(12)
(13)
(14)
(10)
(7)
(6)
(5)
(4)
(3)
(4)
(5)
(6)
(10)
(11)
(11)
Selling, General & Administrative
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
0
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(2)
(3)
(2)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(2)
(4)
(4)
(3)
Research & Development
0
0
0
0
(0)
0
0
(1)
0
(2)
(4)
(5)
(5)
(7)
(9)
(9)
0
(11)
(11)
(7)
(5)
(4)
(4)
0
(2)
(2)
(3)
(4)
(6)
(7)
(7)
Depreciation & Amortization
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
0
(0)
0
(0)
Other Operating Expenses
0
0
0
0
0
(0)
0
0
(2)
(2)
0
0
0
0
0
0
(10)
0
0
0
0
0
0
(3)
0
0
0
0
0
0
0
Operating Income
(2)
N/A
(2)
-12%
(2)
N/A
(2)
-12%
(2)
+4%
(2)
+3%
(2)
-18%
(3)
-25%
(4)
-30%
(4)
-11%
(5)
-17%
(6)
-15%
(7)
-11%
(9)
-33%
(10)
-14%
(11)
-6%
(12)
-7%
(13)
-14%
(14)
-3%
(10)
+29%
(7)
+30%
(6)
+14%
(5)
+13%
(4)
+24%
(3)
+26%
(4)
-41%
(4)
-10%
(5)
-17%
(10)
-82%
(11)
-11%
(10)
+4%
Pre-Tax Income
Interest Income Expense
0
0
0
0
(0)
(0)
(0)
(0)
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Non-Reccuring Items
(0)
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(2)
(3)
(1)
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
(0)
(0)
0
0
0
0
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Pre-Tax Income
(2)
N/A
(2)
-9%
(2)
+19%
(2)
-14%
(2)
-1%
(2)
+3%
(3)
-21%
(3)
-22%
(4)
-19%
(4)
-9%
(5)
-19%
(6)
-12%
(6)
-8%
(8)
-39%
(10)
-16%
(10)
-7%
(11)
-8%
(15)
-34%
(16)
-7%
(10)
+37%
(7)
+35%
(6)
+13%
(5)
+13%
(4)
+24%
(3)
+25%
(4)
-41%
(4)
-10%
(5)
-16%
(10)
-83%
(11)
-11%
(10)
+8%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
1
1
1
1
1
2
2
2
2
3
3
2
1
1
1
1
1
1
1
1
1
1
1
Income from Continuing Operations
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(3)
(4)
(4)
(5)
(5)
(7)
(8)
(8)
(9)
(12)
(13)
(8)
(5)
(5)
(4)
(3)
(2)
(3)
(4)
(4)
(8)
(9)
(8)
Net Income (Common)
(2)
N/A
(2)
+1%
(2)
+21%
(2)
-19%
(2)
+4%
(2)
+4%
(2)
-36%
(3)
-23%
(3)
-14%
(4)
-9%
(4)
-18%
(5)
-11%
(5)
-9%
(7)
-37%
(8)
-13%
(8)
-5%
(9)
-8%
(12)
-39%
(13)
-7%
(8)
+38%
(5)
+34%
(5)
+15%
(4)
+12%
(3)
+22%
(2)
+25%
(3)
-45%
(4)
-8%
(4)
-12%
(8)
-96%
(9)
-13%
(8)
+9%
EPS (Diluted)
-0.03
N/A
-0.03
N/A
-0.02
+33%
-0.03
-50%
-0.03
N/A
-0.03
N/A
-0.04
-33%
-0.03
+25%
-0.02
+33%
-0.02
N/A
-0.03
-50%
-0.03
N/A
-0.02
+33%
-0.03
-50%
-0.03
N/A
-0.03
N/A
-0.03
N/A
-0.05
-67%
-0.05
N/A
-0.03
+40%
-0.02
+33%
-0.02
N/A
-0.01
+50%
-0.01
N/A
-0.01
N/A
-0.01
N/A
-0.01
N/A
-0.01
N/A
-0.02
-100%
-0.02
N/A
-0.02
N/A

See Also

Summary
ETX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ETX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ETX stock valuation using valuation multiples.
Wall Street Estimates
ETX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ETX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.